The estimated Net Worth of Jeffrey S Glenn is at least $463 Tausend dollars as of 22 December 2022. Jeffrey Glenn owns over 100,000 units of Eiger BioPharmaceuticals Inc stock worth over $314,562 and over the last 9 years he sold EIGR stock worth over $0. In addition, he makes $148,081 as Independent Director at Eiger BioPharmaceuticals Inc.
Sign up
Jeffrey Glenn EIGR stock SEC Form 4 insiders trading
Jeffrey has made over 5 trades of the Eiger BioPharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of EIGR stock worth $128,000 on 22 December 2022.
The largest trade he's ever made was buying 100,000 units of Eiger BioPharmaceuticals Inc stock on 22 December 2022 worth over $128,000. On average, Jeffrey trades about 13,112 units every 171 days since 2016. As of 22 December 2022 he still owns at least 182,355 units of Eiger BioPharmaceuticals Inc stock.
You can see the complete history of Jeffrey Glenn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jeffrey Glenn biography
Dr. Jeffrey Scott Glenn M.D. Ph.D. serves as Independent Director of the Company. He has been a member of Private Eiger’s board of directors since his appointment in 2008 and assumed the same position at the Company in March 2016. Dr. Glenn has been an Associate Professor of Medicine, Division of Gastroenterology & Hepatology, and Microbiology & Immunology at Stanford University School of Medicine since 2000, and the Director of the Center for Hepatitis and Liver Tissue Engineering since 2006. Dr. Glenn is also the scientific founder of Eiger. Dr. Glenn earned an A.B. in biochemistry and French civilization form University of California, Berkeley and both a M.D. and Ph.D. in biochemistry from University of California, San Francisco. He also completed an internal medicine residency and a gastroenterology fellowship at Stanford University Medical Center. Glenn’s qualifications to sit on the board of directors include his medical and research background.
What is the salary of Jeffrey Glenn?
As the Independent Director of Eiger BioPharmaceuticals Inc, the total compensation of Jeffrey Glenn at Eiger BioPharmaceuticals Inc is $148,081. There are 14 executives at Eiger BioPharmaceuticals Inc getting paid more, with David Cory having the highest compensation of $2,871,850.
How old is Jeffrey Glenn?
Jeffrey Glenn is 57, he's been the Independent Director of Eiger BioPharmaceuticals Inc since 2016. There are 7 older and 10 younger executives at Eiger BioPharmaceuticals Inc. The oldest executive at Eiger BioPharmaceuticals Inc is Dr. Colin Hislop, 63, who is the Sr. VP of Clinical & Devel. Operations.
What's Jeffrey Glenn's mailing address?
Jeffrey's mailing address filed with the SEC is C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO, CA, 94306.
Insiders trading at Eiger BioPharmaceuticals Inc
Over the last 9 years, insiders at Eiger BioPharmaceuticals Inc have traded over $3,017,304 worth of Eiger BioPharmaceuticals Inc stock and bought 780,533 units worth $4,706,203 . The most active insiders traders include Richard A Kayne, Edgar Engleman und Partners X Lp Inter West Ma.... On average, Eiger BioPharmaceuticals Inc executives and independent directors trade stock every 70 days with the average trade being worth of $47,232. The most recent stock trade was executed by Richard A Kayne on 31 October 2023, trading 278,239 units of EIGR stock currently worth $72,342.
What does Eiger BioPharmaceuticals Inc do?
eiger inc is a research company located in 500 crescent ct ste 300, dallas, texas, united states.
What does Eiger BioPharmaceuticals Inc's logo look like?
Complete history of Jeffrey Glenn stock trades at Eiger BioPharmaceuticals Inc
Eiger BioPharmaceuticals Inc executives and stock owners
Eiger BioPharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Cory,
President, Chief Executive Officer, Director -
David Apelian,
Director -
Stephana Patton,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Sriram Ryali,
Chief Financial Officer -
David A. Cory M.B.A., R.Ph., R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
James Shaffer,
Chief Business Officer -
David A. Cory R.Ph, MBA,
Bus. Founder, Pres, CEO & Director -
Eldon C. Mayer III, M.B.A.,
Exec. VP & Chief Commercial Officer -
Sriram Ryali M.B.A.,
Chief Financial Officer -
Christine Murray,
Independent Director -
Thomas Dietz,
Independent Chairman of the Board -
Amit Sachdev,
Independent Director -
Evan Loh,
Independent Director -
Eldon Mayer,
Executive Vice President, Chief Commercial Officer -
Jeffrey Glenn,
Independent Director -
Dr. Evan Loh,
CEO of Paratek Pharmaceuticals & Director -
Dr. Jeffrey S. Glenn,
Founder, Scientific Advisor & Independent Director -
Dr. Stephana E. Patton J.D., Ph.D.,
Consultant -
Erik Atkisson,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Dr. Colin Hislop,
Sr. VP of Clinical & Devel. Operations -
Rich Franco M.B.A.,
Sr. VP & Progeria Program Lead -
Dr. Ingrid C. Choong,
Sr. VP of Clinical Devel. -
Charles Bramlage,
Director -
Edgar Engleman,
Director -
Joanne Quan,
Chief Medical Officer -
Eduardo Bruno Martins,
SVP, Liver and Infectious Dise -
Ventures Vi, Llc Vivo Ventu...,
-
James H Welch,
Chief Financial Officer -
Nina S Kjellson,
Director -
Kim Sablich,
-
Partners X Lp Inter West Ma...,
-
Ingrid Choong,
Chief Business Officer -
Erik Atkisson,
GC & Chief Compliance Officer -
Lisa Kelly Croswell,
-
James Vollins,
General Counsel -
Leen Kawas,
-
Richard A Kayne,